1 TITLE PAGE

2

Full title: Fluoroscopy time as a new predictor of short-term outcomes after transcatheter aortic
valve replacement

5

6 **Short title**: Fluoroscopy time as independent predictor in TAVR.

7

Authors' names: Alessandro Cafaro¹ MD (dr.alessandrocafaro@libero.it) (0000-0002-2068-8 7351), Francesco Spione^{2,3} MD (francesco.spio@gmail.com) (0000-0002-9327-5286), Osvaldo 9 Burattini⁴ MD (osvaldoburattini@gmail.com) (0000-0002-6904-5528), Daniele De Feo⁵ MD 10 11 (daniele.df93@gmail.com) (0000-0003-1055-0973),Alessandro Xhelo⁵ MD Palmitessa⁵ 12 (alessandroxhelo2@gmail.com) (0009-0002-5317-8489).Chiara MD 13 (chiara.palmy@gmail.com) (0000-0001-7575-9300),Maurizio D'Alessandro⁵ MD (maurizio.dalessandro23@gmail.com) (0000-0002-4558-8157), Vincenzo Pio Amendola⁵ MD 14 15 (vincenzopioamendola@icloud.com) (0009-0002-7044-6916).Flavio Rimmaudo⁶ MD (rimmaudoflavio@gmail.com) (0000-0001-9846-4564), Andrea Igoren Guaricci⁵, MD, PhD 16 (andrea.guaricci@gmail.com) (0000-0001-7133-4401), Alessandro Santo Bortone⁷ MD PhD 17 18 (alessandrosanto.bortone@uniba.it) (0000-0002-7086-7182), Vincenzo Pestrichella⁸ MD (vpestrichella@yahoo.it), Gaetano Contegiacomo⁹ MD (gconteg@gmail.com) (0000-0002-3422-19 7647), Tullio Tesorio² MD (tulliotesorio@gmail.com) (0000-0002-9118-4612), Giuseppe 20 Iacovelli^{4,5} 21 Colonna¹ (giuseppe.colonna@tin.it), Fortunato MD PhD MD 22 (fortunato.iacovelli@gmail.com) (0000-0002-4620-678X).

24 Authors' affiliations

- ¹ Division of Cardiology, "V. Fazzi" Hospital, Lecce, Italy
- 26 ² Interventional Cardiology Service, "Montevergine" Clinic, GVM Care & Research,
- 27 Mercogliano, Italy
- ³ Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples
- 29 "Federico II", Naples, Italy
- 30 ⁴ Division of Cardiology, "SS. Annunziata" Hospital, Taranto, Italy
- ⁵ Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital,
- 32 Bari, Italy
- ⁶ Division of Cardiology, "Vittorio Emanuele" Hospital, Gela, Italy
- 34 ⁷ Division of University Heart Surgery, Cardiothoracic Department, Policlinico University
- 35 Hospital, Bari, Italy
- ⁸ Interventional Cardiology Service, "Mater Dei" Hospital, Bari, Italy
- ⁹ Interventional Cardiology Service, "Anthea" Clinic, GVM Care & Research, Bari, Italy

38

39 All authors take responsibility for all aspects of the reliability and freedom from bias of the data

40 presented and their discussed interpretation.

- 41
- 42 **Funding:** This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the
Declara-tion of Helsinki, and approved by the Independent Ethics Committee of the Policlinico
University Hospital of Bari, Italy (study number 6244, protocol code 0030669 and date of
approval 04th of March 2020)."

17	Informed (onsont	Statamont.	Informed	concent u	vag obtained	from all	subjects	involve	d in 1	tha
4/	Informed (onsent	Statement:	Informed	l consent w	vas obtained	from all	subjects	involve	a in i	the

48 study.

49

- 50 **For correspondence**: Fortunato Iacovelli, MD PhD (*corresponding author*)
- 51 Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital,
- 52 Piazza Giulio Cesare 11, 70124 Bari, Italy
- 53 E-mail: <u>fortunato.iacovelli@gmail.com</u> Tel.: +393200931665 Fax: +390805478796
- 54
- 55

56 **Conflicts of interest**: Gaetano Contegiacomo serves as transcatheter heart valve proctor for 57 Abbott; Fortunato Iacovelli and Francesco Spione directly received speaker fees from General 58 Electric Healthcare; the remaining authors have no conflicts of interest to declare.

59

60 ABSTRACT

61

62 **Objective:** Transcatheter aortic valve replacement (TAVR) is a cine-fluoroscopic guided 63 procedure. The amount of radiation used during the procedure is strictly related with fluoroscopy 64 time (FT) that has been demonstrated to be associated with outcomes and complexity of 65 procedure in percutaneous coronary interventions. The aim of our study is to demonstrate the 66 relationship between FT and short-term outcomes after TAVR.

67 Methods: After splitting 1797 consecutive patients according to tertiles of FT, the composite
68 endpoint early safety (ES) was adjudicated according to Valve Academic Research Consortium

69 (VARC)-2 and -3 consensus documents and the composite endpoints of device success (DS) and
 70 technical success (TS) according to VARC-3 criteria.

Results: The absence of all outcomes (TS, DS, and ES according to VARC-3 and ES according to VARC-2) was significantly associated with higher FT and this association persisted after propensity score matching analysis. Notwithstanding, after receiver operating characteristic analysis, only the FT cut-offs identified for VARC-3 TS and VARC-2 ES had adequate diagnostic accuracy in identifying the absence of these endpoints.

76 Conclusions: Longer FT is related with peri-procedural and short-term outcomes after the 77 procedure, especially in those that are more complex. A FT duration of more than 30 minutes has

an adequate accuracy in identifying VARC-3 technical failure and absence of VARC-2 ES.

79

What is already known on this topic: FT is related with complexity and outcomes in PCI. No
data is available about FT and TAVR.

What this study adds: FT >30 minutes has an adequate accuracy in identifying VARC-3
technical failure and absence of VARC-2 ES.

How this study might affect research, practice or policy: FT that lasts more than 30 minutes in TAVR is linked independently to short-term adverse outcomes after TAVR. A strict follow-up is needed in this procedural setting as FT is a new independent predictor of adverse outcome after TAVR.

88

Keywords: aortic stenosis; transcatheter aortic valve implantation; fluoroscopy; technical
success; early safety; Valve Academic Research Consortium.

92 **TEXT**

93 **1. Introduction**

Transcatheter aortic valve replacement (TAVR) is an established treatment for pa-tients with aortic valve stenosis at high surgical risk or considered inadequate for con-ventional surgical aortic valve replacement (SAVR). Multiple observational and random-ized clinical trials have demonstrated the feasibility and efficacy of this treatment [1-10]. Notwithstanding, recent randomized trials have demonstrated that this percutaneous technique is non-inferior to SAVR also in intermediate and low surgical risk patients [11-15].

100 TAVR is a cine-fluoroscopic guided procedure, and the amount of radiation used is potentially 101 dangerous for both operators and patients because of its stochastic and de-terministic adverse 102 effects [16,17]. The radiation dose, which is strictly related to fluoros-copy time and procedure 103 length, has been demonstrated to be similar to other percuta-neous coronary interventions of 104 moderate complexity [18-20].

105 To date, no study has investigated the association between FT and short-term prog-nosis after 106 TAVR. In particular, in the Valve Academic Research Consortium (VARC) documents [21,22], 107 early safety (ES) and device success (DS) are short-term composite endpoints. ES combines all-108 cause mortality, all stroke, life-threatening bleeding, stage 2 or 3 acute kidney injury (AKI), 109 coronary artery obstruction requiring intervention, and valve-related dysfunction requiring 110 another aortic valvular procedure within 30 days after TAVR. DS combines the absence of 111 procedural mortality, correct positioning of a single prosthetic heart valve into the proper 112 anatomical location and intended performance of the prosthetic heart valve. The VARC-3 113 consensus document added the endpoint technical success (TS) which is a composite of freedom 114 from mortality, successful access, delivery of the device, and retrieval of the delivery system,

correct positioning of a single prosthetic heart valve into the proper anatomical location and 115 116 freedom from surgery or intervention related to the devices or to a major vascular or access-117 related, or cardiac structural complications at the exit from procedure room [22]. With respect to 118 ES definition, the VARC-3 document added other adverse events that significantly impact short-119 and long-term prognosis, such as cardiac structural complications, significant (moderate to 120 severe) aortic regurgitation, and new permanent pacemaker (PM) implantation [22]. Finally, the 121 definition of DS in the VARC-3 document added TS among the other endopoints included in the VARC-2 definition [21,22]. 122 123 Our study aims to evaluate for the first time, in a large population, the relationship between FT

- 124 and short-term outcomes after TAVR.
- 125

126 2. Materials and Methods

127 2.1. Study population

This multicenter observational study assessed all consecutive patients who under-went TAVR at
five southern Italy heart centers ("Montevergine" Clinic of Mercogliano, Policlinico University
Hospital, "Anthea" Clinic and "Mater Dei" Hospital of Bari and "V. Fazzi" Hospital of Lecce)
involved in the "Magna Graecia" TAVR registry.

Between March 2011 and April 2023, 1797 consecutive patients (785 males, mean age 80.86±5.71, 1703 transfemoral access) suitable for TAVR were enrolled. All patients underwent preprocedural assessment with transthoracic echocardiography, coronary angiography, computed tomography scan of the heart, aorta and peripheral arteries, carotid artery ultrasonography and multidisciplinary evaluation by the Heart Team. The majority of procedures were performed in a standard cardiac catheterization laboratory with the support of anesthesiology and surgical

138 backup by experienced operators. Device used were balloon-expandable valves (Edwards Sapien 139 XT and Sapien 3; Meril Myval), self-expandable valves (Medtronic CoreValve, Engager, Evolut 140 R and Evolut PRO; Abbott Portico) and others (Boston Lotus; Boston Acurate and Acurate neo; 141 Direct Flow Medical; JenaValve). 142 participating baseline demographics, Each site collected all clinical. laboratory, 143 echocardiographic, surgical risk score, intraprocedural and postprocedural data, in-hospital 144 outcomes and 1-month follow-up outcomes, in the same dedicated archiving software. All the 145 adverse events and the TS, DS and ES composite endpoints were also re-adjudicated 146 retrospectively, by an external committee of interventional cardiologists, according to both 147 VARC-2 and VARC-3 criteria [21,22]. All TAVR-related complications (according VARC-2 148 and VARC-3 definition both separately and then globally considered) were divided by intra- and

post-procedural. Time delay between the end of TAVR procedure and the first post-proceduralcomplication occurrence was also registered.

151 Patients' population was retrospectively divided according to FT (minutes) tertiles and than by 152 enrollment-time tertiles in order to study FT and radiation dose (RD) during TAVR learning 153 curves.

154

155 2.2. Statistical analysis

Statistical analysis was performed using SigmaStat 3.5, SPSS 25.0 and STATA 13.0 softwares. Continuous variables were expressed as the mean \pm standard deviation and median (interquartile ranges) of absolute numbers; categorical variables were expressed as frequencies and percentages. As appropriate, comparisons were made by t-test, Mann Whitney's U-test, one way ANOVA, ANOVA on ranks, Fisher's exact test or χ^2 test. Pairwise multiple comparisons after

161 ANOVAs were conducted through Holm-Sidak or Dunn's test as properly indicated by 162 definitions. The normal distribution was assessed with Kolmogo-rov-Smirnov tests. A receiver-163 operating characteristic (ROC) curve analysis was built in order to establish the threshold levels 164 of FT that provided the best cut-off for the absence of ES according to VARC-2 and VARC-3 165 definitions. Area under the curve (AUC) values were calculated with confidence intervals (CIs) 166 through concordance statistics to measure test accuracy. The DeLong test was used to identify 167 AUC standard errors. The calibration of FT was evaluated by comparing the mean predicted 168 probability and the mean observed frequency of absence of ES with goodness-of-fit R-squared 169 and Cochran-Armitage tests, calibration plots and estimation of a calibration slope. After this, 170 new optimal cut-off points for the absence of ES were selected using Youden's tests, reporting 171 Youden's indexes: we evaluated sensitivity and specificity according to these new cut-off points. 172 The relationship between FT and the absence of ES was also analysed after propensity score 173 matching (PSM) including as covariates those factors that were considered to increase the time 174 of the procedure: pre-dilatation, post-dilatation, intra-procedural complications, self expandable 175 valve implantation, pre-TAVR ejection-fraction, pre-TAVR maximum transaortic gradient, 176 trans-apical and direct aortic access. All statistical tests were two-sided. For all tests, a p-value 177 <0.05 was considered statistically significant.

178

179 **3. Results**

- 180 3.1. Baseline Characteristics
- 181 Patients' population was divided according to FT (minutes) tertiles: 1st group 13.94±2.93 min,
- 182 2nd group 21.31±1.99 min and 3rd group 38.31±18.83 min.
- 183 All clinical and preprocedural data of the study population are shown in Table 1.

No statistically significant differences were found in terms of preprocedural characteristics like patients' characteristics, previous cardiovascular history, comorbidities and mortality risk scores. Only echocardiographics parameters like left ventricular ejection fraction (p<0.001) and maximum aortic gradient (p = 0.032) were significantly different between the three groups.

188

189 3.2. Procedural characteristics

190 All procedural, post-procedural data and outcomes are shown in Table 2.

191 Some procedural details, such as transfermoral access (p = 0.005), predilatation (p<0.001), self-

192 expandable bioprosthesis (p = 0.011), valve size >26 mm (p = 0.048), postdi-latation (p<0.001),

193 contrast mean (CM) amount (p<0.001) and RD (p<0.001) were significantly associated with FT.

With respect to complications according to VARC-3 criteria, FT was significantly associated with bleedings (p<0.001), transfusions (p<0.001), vascular complications (p<0.001), percutaneous closure device failure (p = 0.005), cardiac arrest during the procedure (p<0.001) and acute myocardial infarction (p = 0.009). FT resulted also significantly linked (p=0.016) with post-procedural complications and patients in the longest FT group experienced a complication earlier than those with shorter FT (p=0.049). Moreover, longer hospitalizations were significantly associated with higher FT during the TAVR procedure (p<0.001).

Furthermore, figure 1 shows the variation of FT and RD after splitting the population into tertilesaccording to the period of enrollment.

There was no significant difference of FT across the tertiles of enrollment-time (23.54 \pm 15.41; 24.92 \pm 18.13; 24.74 \pm 12.01 min; p = 0.371). On the other hand, there is a significant variation of RD that spanned along the study time (p<0.001). RD significantly decreased between first and second enrolling time tertile, while the slight RD increase between second and third tertiles

207 resulted not significant after pairwise comparisons (1143.96±82.72 vs 1449.70±73.23 mGY;
208 p=0.175).

209 3.3. *Outcomes*

Table 2 also shows outcomes incidence and its relationship with FT. Concerning outcomes according to VARC-3 criteria, higher FT was significantly associated with lower TS and DS (p<0.001 and p = 0.021 respectively) and higher absence of ES (p = 0.013). Also considering VARC-2 criteria, the absence of ES was significantly associated with the fluoroscopy time (p<0.001).

215 Furthermore, table 3 describes the relation between FT and outcomes, intended as TS, DS and 216 ES according to VARC-3 criteria and ES according to VARC-2 criteria, after PSM. PSM was 217 performed including, as covariates, all those variables that were considered to be likely to 218 influence FT: pre-dilatation, post-dilatation, intraprocedural complications (according each 219 VARC-2 or -3 outcome), self-expandable valve implantation, pre-TAVR ejection fraction, pre-220 TAVR maximum transaortic gradient, other vascular access than femoral one. After PSM, higher 221 FT was still significantly related with the absence of TS (p = 0.001), DS (p < 0.001) and ES (p =222 0.035), according to VARC-3 criteria, and the absence of ES (p = 0.046) according to VARC-2 223 criteria.

Moreover, the ROC analysis showed a significant correlation between FT and these outcomes (Table 4, Figure 2). Nevertheless, based on the AUC of the cut-off values established with the highest Youden's indexes, a good performance was demonstrated only in detecting TS (Cut-off 27.8±0.04 min) according to VARC-3 criteria and ES (Cut-off 30.1 ± 0.03 min) according to VARC-2 criteria (ES-VARC-3: AUC 0.545, 95% CI 0.518–0.571, sensitivity 29.5%, specificity 80%, p = 0.008; DS-VARC-3: AUC 0.608, 95% CI 0.581–0.633, sensitivity 60.56%, specificity

- 230 57.89%, p < 0.001, TS-VARC-3: AUC 0.680, 95% CI 0.654-0.704, sensitivity 54.17%,
- 231 specificity 76.21%, p <0.001; ES-VARC-2: AUC 0.628, 95% CI 0.601-0.654, sensitivity
- 232 41.28%, specificity 81.53%, p <0.001).

X7 · 11	A 11	Fluoroscopy Time						
Variable	All	1^{st}	2 nd	3rd	р			
Patients characteristics			·	·				
Age (years)	80.86±5.71	80.72±5.59	80.61±6.13	81.17±5.48	0.403			
Male	785/1797 (43.68%)	206/491 (41.95%)	210/438 (47.94%)	220/463 (47.52%)	0.118			
Body Mass Index (kg/m ²)	27.34±4.73	27.34±4.77	27.20±4.32	27.48±5.07	0.802			
Hypertension	1690/1785 (94.68%)	453/486 (93.21%)	409/437 (93.59%)	433/457 (94.75%)	0.597			
Diabetes mellitus	577/1788 (32.27%)	160/488 (32.79%)	149/437 (34.10%)	154/458 (33.62%)	0.912			
Insulin	238/1759 (13.53%)	65/483 (13.46%)	71/424 (16.74%)	72/447 (16.11%)	0.339			
Dyslipidemia	1170/1786 (65.51%)	320/487 (65.71%)	296/437 (67.73%)	304/457 (66.52%)	0.807			
Smoking	122/1744 (6.99%)	40/483 (8.28%)	23/421 (5.46%)	28/436 (6.42%)	0.227			
Anemia	977/1782 (54.83%)	254/490 (51.84%)	239/435 (54.94%)	267/459 (58.17%)	0.147			
COPD	452/1786 (25.31%)	122/487 (25.01%)	111/437 (25.40%)	138/458 (30.13%)	0.151			
Neurological dysfunction	146/1759 (8.30%)	36/483 (7.45%)	35/427 (8.20%)	35/451 (7.76%)	0.916			
Severe liver disease	41/1783 (2.30%)	13/488 (%)	10/435 (%)	10/457 (%)	0.882			
PAD	421/1758 (23.95%)	128/483 (26.50%)	90/428 (21.03%)	109/451 (24.17%)	0.155			
Carotid stenosis ≥50%	45/1354 (3.23%)	6/297 (%)	10/338 (%)	15/345 (%)	0.235			
Critical preoperative state	66/1779 (3.71%)	18/485 (3.71%)	23/435 (5.29%)	18/456 (3.95%)	0.454			
CAD history	448/1784 (25.11%)	125/488 (25.61%)	109/436 (25.00%)	130/456 (28.51%)	0.441			
Prior myocardial infarction	255/1786 (14.28%)	76/488 (15.57%)	64/436 (14.68%)	86/457 (18.82%)	0.208			
Prior cardiac surgery	253/1787 (14.16%)	68/489 (13.91%)	68/437 (15.56%)	72/458 (15.72%)	0.687			
Prior myocardial	406/1791 (22.68%)	119/489 (24.33%)	95/437 (21.74%)	118/459 (25.71%)	0.370			
revascularization								
PCI	248/1791 (13.85%)	76/489 (15.54%)	48/437 (10.98%)	74/459 (16.12%)	0.056			
CABG	92/1791 (5.14%)	28/489 (5.73%)	27/437 (6.18%)	26/459 (5.66%)	0.938			
PCI + CABG	66/1791 (3.69%)	15/489 (3.07%)	20/437 (4.58%)	18/459 (3.92%)	0.486			
Myocardial revascularization for	271/1791 (15.13%)	67/486 (13.79%)	54/437 (12.36%)	65/463 (14.04%)	0.728			
TAVR								
PCI	266/1791 (14.85%)	66/486 (13.58%)	53/437 (12.13%)	62/463 (13.39%)	0.781			
CABG	4/1791 (0.22%)	1/486 (0.21%)	1/437 (0.23%)	2/463 (0.43%)	0.778			
PCI + CABG	1/1791 (0.05%)	0/486 (0.00%)	0/437 (0.00%)	1/463 (0.22%)	0.369			
Residual significant CAD	214/1782 (12.01%)	60/483 (12.42%)	48/437 (12.34%)	49/459 (10.67%)	0.666			

233 Table 1. Baseline characteristics of the study population according to FT tertiles

during TAVR							
Prior PM/ICD/CRT implantation	222/1772 (12.53%)	57/485 (11.75%)	49/433 (11.32%)	62/454 (13.66%)	0.522		
NYHA functional class III-IV	1475/1786 (82.59%)	402/487 (82.55%)	355/437 (81.24%)	356/457 (77.90%)	0.181		
СКД	743/1797 (41.35%)	212/491 (43.18%)	178/438 (40.64%)	200/463 (43.20%)	0.671		
Electrocardiography		, . (,					
Sinus rhythm	1462/1788 (81.77%)	390/488 (79.92%)	354/437 (81.01%)	383/458 (83.62%)	0.325		
Atrial fibrillation / flutter	326/1788 (18.23%)	98/488 (20.08%)	83/437 (18.99%)	1%) 385/438 (83.82%) 9%) 75/458 (16.38%)			
PM-induced rhythm	94/1788 (5.26%)	31/488 (6.35%)	24/437 (5.49%)	24/458 (5.24%)	0.741		
Echocardiography	. ,	, ,					
LVEF (%)	53.345±10.21	54.22±10.81	52.88±10.47	52.33±9.77	< 0.001		
Maximum aortic gradient	75.67±21.22	73.43±20.45	77.38±20.00	76.33±22.69	0.032		
(mmHg)							
Mean aortic gradient (mmHg)	46.40±14.33	45.27±14.29	47.21±13.23	46.92±14.93	0.074		
Moderate-to-severe mitral	679/1678 (40.46%)	175/455 (38.46%)	179/407 (43.98%)	194/429 (45.22%)	0.095		
regurgitation							
Pulmonary arterial systolic	40.22±13.37	40.23±12.47	39.72±12.84	40.07±12.83	0.834		
pressure (mmHg)							
Mortality risk scores							
Logistic EuroSCORE	16.14±12.31	16.04±12.76	15.94±12.18	5.94±12.18 17.49±13.55			
EuroSCORE II	5.79±12.75	5.61±5.84	5.26±5.35	6.04±6.79	0.283		
STS-PROM	4.60±3.55	4.70±3.60	4.47±3.45	4.96±4.32	0.077		
STS-PROM≥8	176/1779 (9.90%)	45/486 (9.26%)	44/435 (10.11%)	60/453 (13.24%)	0.122		

234 COPD = chronic obstructive pulmonary disease; PAD = peripheral artery disease; CAD = coronary artery disease; PCI = percutaneous coronary intervention;

CABG = coronary artery by-pass grafting; TAVR = transcatheter a ortic valve replacement; PM = pacemaker; ICD = implantable cardioverter-defibrillator; CRT = cardiac resynchronization therapy; NYHA = New York Heart Association; CKD = chronic kidney disease; LVEF = left ventricular ejection fraction;

237 EuroSCORE = european system for cardiac operative risk evaluation; STS-PROM = Society of Thoracic Surgery predictive risk of mortality.

238

239 Table 2. Procedural features and outcomes according to FT tertiles

		Fluoroscopy Time					
Variable	All	1 st	2 nd	3 rd	р		
Procedural details							
Transfemoral access route	1703/1797 (94.77%)	444/491 (90.43%)	416/438 (94.98%) 440/463 (95.03%)		0.005		

Other access routes	94/1797 (5.23%)	47/491 (9.57%)	22/438 (5.02%)	23/463 (4.97%)	0.005
Trans-subclavian	27/1797 (1.57%)	9/491(1.83%)	6/438 (1.37%)	12/463 (2.59%)	0.404
transapical	57/1797 (3.17%)	36/491 (7.33%)	10/438 (2.28%)	9/463 (1.94%)	< 0.001
direct aortic	8/1797 (0.44%)	1/491(0.20%)	6/438 (1.37%)	1/463 (0.22%)	0.029
Orotracheal intubation	233/1796 (12.97%)	73/491 (14.87%)	66/437 (15.10%)	90/463 19.44%)	0.107
Valve-in-valve	73/1794 (4.07%)	16/491 (3.26%)	20/437 (4.58%)	27/461 (5.86%)	0.157
Pre-dilation	827/1784 (46.36%)	186/489 (38.04%)	248/436 (56.88%)	282/456 (61.84%)	< 0.001
Valve kind					
balloon-expandable	551/1797 (30.66%)	190/491 (38.70%)	153/438 (34.93%)	130/463 (28.08%)	0.002
self-expandable	1124/1797 (62.55%)	266/491 (54.17%)	248/438 (56.62%)	294/463 (63.50%)	0.011
others	122/1797 (6.79%)	35/491 (7.13%)	37/438 (8.45%)	39/463 (8.42%)	0.691
Valve Size >26 mm	722/1793 (40.27%)	175/489 (35.79%)	166/438 (37.90%)	200/461 (43.38%)	0.048
Post-dilation	479/1795 (26.68%)	97/491 (19.76%)	112/436 (25.69%)	145/463 (31.32%)	< 0.001
CM volume (mL)	149.97±76.36	130.431±54.03	161.14±67.22	197.61±96.94	< 0.001
Radiation Dose (mGY)	1366.18±1241.57	1070.68±1051.40	1381.24±1070.11	2112.15±1748.60	< 0.001
Complications and outcomes (VAR	C-3)				
AKI	272/1714 (15.87%)	70/472 (14.83%)	50/420 (11.90%)	72/433 (16.63%)	0.142
CVVH	41/1730 (2.37%)	10/476 (2.10%)	8/420 (1.90%)	15/438 (3.42%)	0.288
Chronic hemodialysis	9/1667 (0.54%)	3/460 (0.65%)	2/409 (0.49%)	4/423 (0.95%)	0.724
Bleeding (VARC-3)	588/1399 (48.03%)	124/343 (36.15%)	139/313 (44.41%)	214/362 (59.12%)	< 0.001
Type 1	192/ (13.72%)	34/343 (9.91%)	55/313 (17.57%)	72/362 (19.89%)	< 0.001
Type 2	307/1399 (21.94%)	67/343 (19.53%)	67/313 (21.41%)	102/362 (28.18%)	0.017
Type 3-5	89/1399 (6.36%)	23/343 (6.71%)	17/313 (5.43%)	40/362 (11.05%)	0.016
BARC≥3	561/1773 (32.37%)	124/477 (26.00%)	117/424 (27.59%)	208/449 (46.32%)	< 0.001
Need of transfusion	298/1721 (17.31%)	61/475 (12.84%)	65/419 (15.51%)	108/442 (24.43%)	< 0.001
1 unit	140/1721 (8.13%)	30/475 (6.32%)	31/419 (7.40%)	52/442 (11.76%)	0.008
2 units	106/1721 (6.16%)	23/475 (4.84%)	23/419 (5.49%)	38/442 (8.60%)	0.046
>2 units	52/1721 (3.02%)	8/475 (1.68%)	11/419 (2.62%)	18/442 (4.07%)	0.086
Vascular complications	286/1765 (16.20%)	59/484 (12.19%)	57/436 (13.07%)	118/455 (25.93%)	< 0.001
minor	170/1765 (9.63%)	41/484 (8.47%)	34/436 (7.80%)	65/455 (14.29%)	0.002
major	116/1765 (6.57%)	18/484 (3.72%)	23/436 (5.27%)	53/455 (11.65%)	< 0.001
Access-site related vascular	224/339 (66.08%)	22/69 (31.88%)	43/86 (50.00%)	47/137 (34.31%)	0.029
complications					

PCD failure	101/1556 (6.49%)	20/404 (4.72%)	22/373 (5.90%)	40/387 (10.34%)	0.005
At least moderate residual aortic	129/1562 (8.26%)	26/412 (6.31%)	30/377 (7.96%)	38/398 (9.55%)	0.223
regurgitation					
Permanent PM implantation	226/1572 (14.38%)	51/419 (12.17%)	64/484 (16.67%)	60/381 (15.75%)	0.163
ECM/cardiac arrest	66/1713 (3.85%)	15/473 (3.17%)	7/425 (1.65%)	34/440 (7.73%)	< 0.001
New-onset atrial	124/1412 (8.78%)	33/375 (8.80%)	25/343 (7.29%)	33/376 (8.78%)	0.707
fibrillation/flutter					
Acute myocardial infarction	19/1774 (1.07%)	2/486 (0.41%)	3/437 (0.69%)	11/454 (2.42%)	0.009
Stroke/TIA	34/1773 (1.92%)	6/487 (1.23%)	8/437 (1.83%)	7/453 (1.54%)	0.759
Hospital length of stay (days)	5.73±9.63	4.99±3.52	5.53±3.93	6.34±4.46	< 0.001
Hospital length of stay>5days	627/1722 (36.41%)	139/472 (29.45%)	160/424 (37.74%)	194/431 (45.01%)	< 0.001
Technical success	1612/1752 (92.01%)	456/480 (95.00%)	406/431 (94.20%)	382/453 (84.33%)	< 0.001
Device success	1562/1764 (88.55%)	442/485 (91.13%)	383/431 (88.86%)	385/451 (85.37%)	0.021
Periprocedural mortality	43/1734 (2.48%)	10/475 (2.10%)	10/423 (2.36%)	19/452 (4.21%)	0.118
Mortality at one year (F-U)	59/1686 (3.50%)	19/465 (4.09%)	10/413 (2.42%)	20/432 (4.63%)	0.212
Early safety absence (VARC-2)	222/1732 (12.82%)	42/477 (8.80%)	43/426 (10.09%)	87/449 (19.38%)	< 0.001
Early safety absence (VARC-3)	559/1732 (32.27%)	141/477 (29.56%)	115/426 (26.99%)	161/449 (35.86%)	0.013
Post-procedural complications	427/839 (50.89%)	91/203 (44.83%)	100/188 (53.19%)	146/250 (58.40%)	0.016
(VARC-2 and VARC-3)					
Complication time-delay (days)	3.44±39.39	3.13±18.55	6.99±79.80	2.55±11.97	0.049
from TAVR					

AKI = acute kidney injury; CVVH = continuous venovenous haemofiltration; PCD = percutaneous closure device; ECM = esternal cardiac massage; TIA =

transient ischemic attack; F-U = follow up; VARC = Valve Academic Research Consortium

Variable	Early Safet	y (VARC-3)	~	T-statistic
Valiable	Yes	No	р	Yes
Fluoroscopy Time min (unmatched)	23.58±1.80	28.23±1.80	<0.001	23.58±1.80
Fluoroscopy Time min (matched after	24.09±3.17	28.23±3.17	0.035	24.09±3.17
PSM*)				
	Device Succe	ess (VARC-3)	n	
	Yes	No	Ч	
Fluoroscopy Time min (unmatched)	23.70±1.93	31.95±1.93	<0.001	4.27
Fluoroscopy Time min (matched after	22.83±2.76	32.23±2.76	0.007	3.41
PSM*)				
	Technica	р		
	Yes	No		
Fluoroscopy Time min (unmatched)	23.82±2.32	37.99±2.32	< 0.001	2.58
Fluoroscopy Time min (matched after	22.01±4.23	37.99±4.23	0.001	1.90
PSM*)				
	Early Safet	y (VARC-2)	р	
	Yes	No		
Fluoroscopy Time min (unmatched)	33.72±2.05	23.72±3.05	<0.001	4.87
Eluoroscopy Time min (matched after	33 72+3 10	22.11+3.10	0.046	3.74
riderescopy rime rim (matched diter	55.72±5.10			-

249 Table 3. Relationship between fluoroscopy time and outcomes before and after propensity score matching (PSM)

260 Table 4. ROC analysis of VARC-2 and VARC-3 outcomes according to FT

261

											2.62
	AUC ± DeLong standard	95% CI	Asymptotic significance	Cut- off	Youden index	Sensitivity (%)	Specificity (%)	Accuracy (%)	LR- /LR+	Adjusted R-square	Slope 263
	error										264
No Early Safety	0.628±0.0 24	0.601- 0.654	<0.001	$\begin{array}{c} 30.1 \pm \\ 0.03 \end{array}$	0.229	41.28	81.53	76.41%	0.72- 2.23	0.032	2.65 9
(VARC-2)											266
No Early Safety (VARC-3)	0.545±0.0 17	0.518- 0.571	0.008	$\begin{array}{c} 30.00 \\ \pm 0.02 \end{array}$	0.108	29.50	80.86	65.01%	0.87- 1.54	0.011	2 6 98
No Device Success (VARC-2)	0.590±0.0 24	0.564- 0.616	<0.001	22±0. 04	0.158	58.60	56.28	56.55%	0.73- 1.34	0.009	2696
No Device Success (VARC-3)	0.608±0.0 21	0.581- 0.633	<0.001	22±0. 03	0.195	60.56	57.89	58.40%	0.78- 1.44	0.026	270 0.948 271
No Technical Success (VARC-3)	0.680±0.0 28	0.654- 0.704	<0.001	27.8± 0.04	0.305	54.17	76.21	74.27%	0.60- 2.27	0.046	272 0.886 273 274

275 VARC = Valve Academic Research Consortium; AUC = area under the curve; CI = confidence index.



Figure 1. TAVR learning curve. Fluoroscopy time and Radiation dose (mean and standard
deviation) according to TAVR enrollment time tertiles (1st tertile: 598 patients from April 2011

to September 2017; 2nd tertile: 600 patients from October 2017 to November 2020; 3rd tertile:



280 59

Figure 2. Absence of ES, DS and TS according to FT: ROC curve analysis.9 patients from
December 2020 to april 2023). NS: not significant.

283

285 4. Discussion

The main findings of our study can be summarized as follows: 1) longer FT during TAVR is related to more complex procedure; 2) short-term outcomes after TAVR are related with FT and this association persists after PSM; 3) the cut-offs identified after ROC analysis have sufficient accuracy to detect VARC-3 TS and VARC-2 ES; 4) the variation over time of FT is non significantly related with TAVR learning curve.

291 Our study is the first large TAVR cohort in which has been investigated the relationship between FT and short-term outcomes after the last updated consensus document VARC-3 [22]. Previous 292 293 studies have demonstrated that prolonged FT is associated with more complex lesions treated in 294 percutaneous coronary intervention [23-25]. In our analysis a longer FT is associated with 295 transfemoral access approach and a more challenging procedure: need of pre-dilatation and post-296 dilatation, self-expandable valve implantation, higher CM amount used and higher radation dose 297 produced during the procedure. However, the higher length of FT when transfemoral access is 298 used instead of a surgical approach (like trans-apical and trans-sublacvian) is easily explained by 299 the fact that in the first case the management of the access is completely cine-fluoroscopic 300 guided in the majority of procedures.

To date, no study analyzed the relationship between FT and short-term outcomes (according VARC-2 and -3 definitions) in TAVR. Only radiation exposure during the procedure has been investigated and has been shown to be comparable to percutaneous coronary intervention of moderate complexity [18-20]. Unlike radiation exposure, FT is independent by biometric parameters such as BMI. Interestingly, in our study the absence of all short-term outcomes (VARC-3 TS, DS and ES and VARC-2 ES) is significantly associated with longer FT and this association persists after PSM including as covariates all variables that could influence the length

308 of the procedure, including intra-procedural complications. FT appears to be an independent 309 predictor of short-term TAVR-related post-procedural complications. This could be explained by 310 the fact that in interventional cardiology the less procedures last, the fewer are the complications 311 and consequently the better are the outcomes.

312 However, although the ROC analysis showed a significant correlation between the FT and these 313 outcomes, the identified cut-offs do not have adequate diagnostic accuracy in adjudicating DS 314 and ES according to VARC-3 criteria, due to the fact that their AUC was never above 0.6. 315 Conversely, the cut-offs of 27.8±0.04 min for TS according to VARC-3 and of 30.1±0.03 for ES 316 according to VARC-2 have adequate diagnostic accuracy. These values show that when the FT 317 lasts more than 30 minutes, it is more likely that the patient might have to experience technical 318 failure at the exit of the catheterization laboratory or might have short-term complications 319 according VARC-2 and VARC-3 definitions.

The reason why this cut-off is able to predict the absence of ES-VARC-2 instead of ES VARC-3 can properly be explained by the possible limits of new VARC-3 criteria: the more complications are included in this composite endpoint, the more its diagnostic performance will decrease. Indeed, as previously reported, even the accuracy of the mortality risk score is lower with VARC-3 than with VARC-2 criteria [26].

Finally, looking at TAVR learning curve (Figure 1), there was no significant variation in FT, while a significant reduction of RD administered during the period of enrollment resulted significant only between the first and the second tertile of en-rollment period. This finding could be explained by the fact that the first tertile of enrollment, covering about 7 years, spanned for a longer time than the second and the third ones. So the first tertile of enrollment comprehends the most of the learning curve. The RD reduction is maybe related to technological advancements of

331 the newer radiological angiographers. Another explanation is that the majority of invasive 332 coronary angiography were performed simultaneously with TAVR in the third tertile of 333 enrollment-time. Thus, even though the operators improved their skills there wasn't a decrease of 334 both FT and RD between the second and third period of TAVR enrollment due to the fact that 335 more procedures were performed at the same time. However our data showed no significative 336 increase in the revascularization rate during TAVR according to FT tertiles, so an indirect 337 linkage between FT and myocardial injury related to myocardial revascularization during TAVR 338 could be excluded.

339

340 **5. Limitations**

Although it was obtained from a prospectively collected database, this is an unspecified post-hoc analysis. Therefore, we cannot exclude that potential confounding factors not considered in the model may have influenced the results. The effect of a learning curve and changes in treatment strategy is also heterogeneous, as the study spanned more than a decade. Furthermore, we believe that aspects of management not controlled or specified may have been a source of bias. Finally, an independent committee did not adjudicate all clinical events that were site-referred.

347

348 6. Conclusions

FT is an easily available parameter during TAVR. This is the first study that evaluated the relationship between FT and short-term outcomes after TAVR. Longer FT is related to periprocedural and short-term outcomes after TAVR, expecially in more complex procedures. This relation is independent from intra-procedural complications after PSM analysis. A FT duration of more than 30 minutes has an adequate accuracy in identifying VARC-3 technical failure and

- absence of VARC-2 ES. Defining ES according to the most recent VARC-3 consensus document
- invalidates the accuracy of this relation, probably because of the inclusion of additional frequent
- adverse events such as permanent PM implantation.
- 357
- 358 Acknowledgments: Francesco Spione has been supported by a research grant provided by the
- 359 Cardiopath PhD program.
- 360 Acknowledgment of grant support: none.
- 361
- 362 Data Availability Statement: Data are accessible with the article (raw data are available upon
 363 individual request).
- **364 REFERENCES**
- 365 1. Smith, C.R.; Leon, M.B.; Mack, M.J.; Miller, D.C.; Moses, J.W.; Svensson, L.G.; Tuzcu,

366 E.M.; Webb, J.G.; Fontana, G.P.; Makkar, R.R.; et al. Transcatheter versus surgical aortic-valve 367 replacement in high-risk patients. Ν Engl J Med 2011, 364. 2187-2198, 368 doi:10.1056/NEJMoa1103510.

2. Lefèvre, T.; Kappetein, A.P.; Wolner, E.; Nataf, P.; Thomas, M.; Schächinger, V.; De

370 Bruyne, B.; Eltchaninoff, H.; Thielmann, M.; Himbert, D.; et al. One year follow-up of the multi-

371 centre European PARTNER transcatheter heart valve study. Eur Heart J 2011, 32, 148-157,
372 doi:10.1093/eurheartj/ehq427.

373 3. Eltchaninoff, H.; Prat, A.; Gilard, M.; Leguerrier, A.; Blanchard, D.; Fournial, G.; Iung,
 374 B.; Donzeau-Gouge, P.; Tribouilloy, C.; Debrux, J.L.; et al. Transcatheter aortic valve
 375 implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards)
 376 registry. Eur Heart J 2011, 32, 191-197, doi:10.1093/eurheartj/ehq261.

Thomas, M.; Schymik, G.; Walther, T.; Himbert, D.; Lefèvre, T.; Treede, H.; Eggebrecht,
H.; Rubino, P.; Michev, I.; Lange, R.; et al. Thirty-day results of the SAPIEN aortic
Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter
aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010, 122, 62-69,
doi:10.1161/circulationaha.109.907402.

382 5. Rodés-Cabau, J.; Webb, J.G.; Cheung, A.; Ye, J.; Dumont, E.; Feindel, C.M.; Osten, M.;
383 Natarajan, M.K.; Velianou, J.L.; Martucci, G.; et al. Transcatheter aortic valve implantation for
384 the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive
385 surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol
386 2010, 55, 1080-1090, doi:10.1016/j.jacc.2009.12.014.

Petronio, A.S.; De Carlo, M.; Bedogni, F.; Marzocchi, A.; Klugmann, S.; Maisano, F.;
 Ramondo, A.; Ussia, G.P.; Ettori, F.; Poli, A.; et al. Safety and efficacy of the subclavian
 approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ
 Cardiovasc Interv 2010, 3, 359-366, doi:10.1161/circinterventions.109.930453.

391 7. Leon, M.B.; Smith, C.R.; Mack, M.; Miller, D.C.; Moses, J.W.; Svensson, L.G.; Tuzcu,

E.M.; Webb, J.G.; Fontana, G.P.; Makkar, R.R.; et al. Transcatheter aortic-valve implantation for
aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010, 363, 1597-1607,

394 doi:10.1056/NEJMoa1008232.

395 8. Himbert, D.; Descoutures, F.; Al-Attar, N.; Iung, B.; Ducrocq, G.; Détaint, D.; Brochet,

396 E.; Messika-Zeitoun, D.; Francis, F.; Ibrahim, H.; et al. Results of transfemoral or transapical
397 aortic valve implantation following a uniform assessment in high-risk patients with aortic

398 stenosis. J Am Coll Cardiol 2009, 54, 303-311, doi:10.1016/j.jacc.2009.04.032.

9. Piazza, N.; Grube, E.; Gerckens, U.; den Heijer, P.; Linke, A.; Luha, O.; Ramondo, A.;
Ussia, G.; Wenaweser, P.; Windecker, S.; et al. Procedural and 30-day outcomes following
transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving
system: results from the multicentre, expanded evaluation registry 1-year following CE mark
approval. EuroIntervention 2008, 4, 242-249, doi:10.4244/eijv4i2a43.

- 404 10. Grube, E.; Buellesfeld, L.; Mueller, R.; Sauren, B.; Zickmann, B.; Nair, D.; Beucher, H.;
 405 Felderhoff, T.; Iversen, S.; Gerckens, U. Progress and current status of percutaneous aortic valve
 406 replacement: results of three device generations of the CoreValve Revalving system. Circ
 407 Cardiovasc Interv 2008, 1, 167-175, doi:10.1161/circinterventions.108.819839.
- Leon, M.B.; Smith, C.R.; Mack, M.J.; Makkar, R.R.; Svensson, L.G.; Kodali, S.K.;
 Thourani, V.H.; Tuzcu, E.M.; Miller, D.C.; Herrmann, H.C.; et al. Transcatheter or Surgical
 Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016, 374, 1609-1620,
 doi:10.1056/NEJMoa1514616.

Mack, M.J.; Leon, M.B.; Thourani, V.H.; Makkar, R.; Kodali, S.K.; Russo, M.; Kapadia,
S.R.; Malaisrie, S.C.; Cohen, D.J.; Pibarot, P.; et al. Transcatheter Aortic-Valve Replacement
with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019, 380, 1695-1705,
doi:10.1056/NEJMoa1814052.

D'Errigo, P.; Barbanti, M.; Ranucci, M.; Onorati, F.; Covello, R.D.; Rosato, S.;
Tamburino, C.; Santini, F.; Santoro, G.; Seccareccia, F. Transcatheter aortic valve implantation
versus surgical aortic valve replacement for severe aortic stenosis: results from an intermediate
risk propensity-matched population of the Italian OBSERVANT study. Int J Cardiol 2013, 167,
1945-1952, doi:10.1016/j.ijcard.2012.05.028.

- 421 14. Thyregod, H.G.; Steinbrüchel, D.A.; Ihlemann, N.; Nissen, H.; Kjeldsen, B.J.; Petursson,
- 422 P.; Chang, Y.; Franzen, O.W.; Engstrøm, T.; Clemmensen, P.; et al. Transcatheter Versus
- 423 Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year
- 424 Results From the All-Comers NOTION Randomized Clinical Trial. J Am Coll Cardiol 2015, 65,
- 425 2184-2194, doi:10.1016/j.jacc.2015.03.014.
- 426 15. Popma, J.J.; Deeb, G.M.; Yakubov, S.J.; Mumtaz, M.; Gada, H.; O'Hair, D.; Bajwa, T.;
- 427 Heiser, J.C.; Merhi, W.; Kleiman, N.S.; et al. Transcatheter Aortic-Valve Replacement with a
- 428 Self-Expanding Valve in Low-Risk Patients. N Engl J Med 2019, 380, 1706-1715,
 429 doi:10.1056/NEJMoa1816885.
- 430 16. Chambers, C.E.; Fetterly, K.A.; Holzer, R.; Lin, P.J.; Blankenship, J.C.; Balter, S.;
 431 Laskey, W.K. Radiation safety program for the cardiac catheterization laboratory. Catheter
 432 Cardiovasc Interv 2011, 77, 546-556, doi:10.1002/ccd.22867.
- 433 17. Little, M.P. Risks associated with ionizing radiation. Br Med Bull 2003, 68, 259-275,
 434 doi:10.1093/bmb/ldg031.
- 435 18. Sharma, D.; Ramsewak, A.; O'Conaire, S.; Manoharan, G.; Spence, M.S. Reducing
 436 radiation exposure during transcatheter aortic valve implantation (TAVI). Catheterization and
 437 Cardiovascular Interventions 2015, 85, 1256-1261, doi:https://doi.org/10.1002/ccd.25363.
- 438 19. Daneault, B.; Balter, S.; Kodali, S.K.; Williams, M.R.; Généreux, P.; Reiss, G.R.;
 439 Paradis, J.M.; Green, P.; Kirtane, A.J.; Smith, C.; et al. Patient radiation exposure during
 440 transcatheter aortic valve replacement procedures. EuroIntervention 2012, 8, 679-684,
 441 doi:10.4244/eijv8i6a106.
- 442 20. Michel, J.M.; Hashorva, D.; Kretschmer, A.; Alvarez-Covarrubias, H.A.; Mayr, N.P.;
- 443 Pellegrini, C.; Rheude, T.; Frangieh, A.H.; Giacoppo, D.; Kastrati, A.; et al. Evaluation of a

- Low-Dose Radiation Protocol During Transcatheter Aortic Valve Implantation. Am J Cardiol
 2021, 139, 71-78, doi:10.1016/j.amjcard.2020.10.035.
- 446 21. Kappetein, A.P.; Head, S.J.; Généreux, P.; Piazza, N.; van Mieghem, N.M.; Blackstone,
- E.H.; Brott, T.G.; Cohen, D.J.; Cutlip, D.E.; van Es, G.-A.; et al. Updated standardized endpoint
 definitions for transcatheter aortic valve implantation: the Valve Academic Research
 Consortium-2 consensus document[†]. European Heart Journal 2012, 33, 2403-2418,
 doi:10.1093/eurheartj/ehs255.
- 451 22. Genereux, P.; Piazza, N.; Alu, M.C.; Nazif, T.; Hahn, R.T.; Pibarot, P.; Bax, J.J.; Leipsic,
 452 J.A.; Blanke, P.; Blackstone, E.H.; et al. Valve Academic Research Consortium 3: updated
 453 endpoint definitions for aortic valve clinical research. Eur Heart J 2021, 42, 1825-1857,
 454 doi:10.1093/eurheartj/ehaa799.
- A.J.; Leon, M.B.; Moses, J.W.; Stone, G.W.; et al. An evaluation of fluoroscopy time and
 correlation with outcomes after percutaneous coronary intervention. J Invasive Cardiol 2007, 19,
- 458 208-213.
- 459 24. Tajti, P.; Ayoub, M.; Nuehrenberg, T.; Ferenc, M.; Behnes, M.; Buettner, H.J.; Neumann,
 460 F.J.; Mashayekhi, K. Association of Prolonged Fluoroscopy Time with Procedural Success of
 461 Percutaneous Coronary Intervention for Stable Coronary Artery Disease with and without
- 462 Chronic Total Occlusion. J Clin Med 2021, 10, doi:10.3390/jcm10071486.
- Ishibashi, S.; Sakakura, K.; Asada, S.; Taniguchi, Y.; Yamamoto, K.; Tsukui, T.;
 Seguchi, M.; Jinnouchi, H.; Wada, H.; Fujita, H. Clinical Factors Associated with Long
 Fluoroscopy Time in Percutaneous Coronary Interventions to the Culprit Lesion of Non-STSegment Elevation Myocardial Infarction. Int Heart J 2021, 62, 282-289, doi:10.1536/ihj.20-634.

467 26. Iacovelli, F.; Loizzi, F.; Cafaro, A.; Burattini, O.; Salemme, L.; Cioppa, A.; Rizzo, F.;
468 Palmitessa, C.; D'Alessandro, M.; De Feo, D.; et al. Surgical Mortality Risk Scores in
469 Transcatheter Aortic Valve Implantation: Is Their Early Predictive Value Still Strong? J.
470 Cardiovasc. Dev. Dis. 2023, 10, doi:10.3390/jcdd10060244.

471

472 LEGEND FOR TABLES AND FOR FIGURES.

473

474 **Table 1.** Baseline characteristics of the study population according to FT tertiles.

475 COPD = chronic obstructive pulmonary disease; PAD = peripheral artery disease; CAD =

476 coronary artery disease; PCI = percutaneous coronary intervention; CABG = coronary artery by-

477 pass grafting; TAVR = transcatheter aortic valve replacement; PM = pacemaker; ICD =

478 implantable cardioverter-defibrillator; CRT = cardiac resynchronization therapy; NYHA = New

479 York Heart Association; CKD = chronic kidney disease; LVEF = left ventricular ejection

480 fraction; EuroSCORE = european system for cardiac operative risk evaluation; STS-PROM =

481 Society of Thoracic Surgery predictive risk of mortality.

482 **Table 2.** Procedural features and outcomes according to FT tertiles.

483 AKI = acute kidney injury; CVVH = continuous venovenous haemofiltration; PCD =

484 percutaneous closure device; ECM = esternal cardiac massage; TIA = transient ischemic attack;

485 F-U = follow up; VARC = Valve Academic Research Consortium.

- 486 Table 3. Relationship between fluoroscopy time and outcomes before and after propensity score
 487 matching (PSM).
- 488 **Table 4.** ROC analysis of VARC-2 and VARC-3 outcomes according to FT.

- 489 VARC = Valve Academic Research Consortium; AUC = area under the curve; CI = confidence
 490 index.
- 491
- 492 Figure 1. TAVR learning curve. Fluoroscopy time and Radiation dose (mean and standard
- 493 deviation) according to TAVR enrollment time tertiles (1st tertile: 598 patients from April 2011
- 494 to September 2017; 2nd tertile: 600 patients from October 2017 to November 2020; 3rd tertile:
- 495 599 patients from December 2020 to april 2023). NS: not significant.
- 496 Figure 2. Absence of ES, DS and TS according to FT: ROC curve analysis.

FLUOROSCOPY TIME



RADIATION DOSE



